Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Resistant Depressive Disorder Clear all
Completed Not applicable Interventional Results available

Vagal Nerve Stimulation for Treatment Resistant Major Depression

NCT04990687
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
gammaCore™
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 29, 2026, 1:17 PM EDT
Not yet recruiting No phase listed Observational

Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients

NCT06101914
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 29, 2026, 1:17 PM EDT
Recruiting Phase 2 Interventional

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

NCT07553637
View directory record Official record
Conditions
Treatment-resistant Depression (TRD)
Interventions
ALTO-207, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
38
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 29, 2026, 1:17 PM EDT
Not yet recruiting Not applicable Interventional

Neuronavigated aiTBS for TRD

NCT07329153
View directory record Official record
Conditions
Treatment Resistant Depression (TRD)
Interventions
aiTBS
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
San Diego, California • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Not applicable Interventional Results available

Insulin Resistance in Patients With Mood Disorder

NCT00242619
View directory record Official record
Conditions
Depression, Bipolar Disorder, Insulin Resistance
Interventions
rosiglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Phase 4 Interventional Results available

Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses

NCT00305565
View directory record Official record
Conditions
Depression
Interventions
VNS Therapy
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
26
States / cities
Tucson, Arizona • Sacramento, California • Marietta, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Sep 29, 2026, 1:17 PM EDT
Not listed No phase listed Observational

Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression

NCT01768052
View directory record Official record
Conditions
Major Depression
Interventions
functional Near Infrared Spectroscopy
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2015 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Not applicable Interventional Results available

Low Frequency TMS for Depression in Epilepsy

NCT03105700
View directory record Official record
Conditions
Epilepsy, Depressions, Refractory
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 29, 2026, 1:17 PM EDT
Completed No phase listed Observational

Using Neuroimaging to Investigate Major Depressive Disorder

NCT00781677
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Anxiety
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 29, 2026, 1:17 PM EDT
Terminated Not applicable Interventional Results available

Cysteamine Therapy for Major Depressive Disorder

NCT00715559
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
cysteamine bitartrate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 29, 2026, 1:17 PM EDT
Terminated Phase 2Phase 3 Interventional

Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder

NCT01504659
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ketamine hydrochloride injection, Flat tonic water (e.g., Canada Dry Tonic Water)
Drug
Lead sponsor
Juvenile Bipolar Research Foundation
Other
Eligibility
6 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Not Predetermined, Connecticut • Maplewood, New Jersey • Not Predetermined, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Not applicable Interventional Results available

Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression

NCT03191058
View directory record Official record
Conditions
Depression, Unipolar Depression, Treatment Resistant Depression
Interventions
Magnetic Seizure Therapy, Electroconvulsive Therapy
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Not applicable Interventional

Fermented Milk Product With Probiotic and Its Impact on Mood of Patients With Treatment Resistant Depression

NCT03317678
View directory record Official record
Conditions
Depression
Interventions
BioKefir, Non-fermented milk
Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 29, 2026, 1:17 PM EDT
Withdrawn Phase 2 Interventional

Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder

NCT05652465
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS)
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 29, 2026, 1:17 PM EDT
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 29, 2026, 1:17 PM EDT
Active, not recruiting Not applicable Interventional

Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder

NCT06670040
View directory record Official record
Conditions
ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder, MDD
Interventions
Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 26 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Phase 2Phase 3 Interventional

Neural and Antidepressant Effects of Propofol

NCT03684447
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Propofol
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

NCT02360280
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
ketamine, midazolam
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 29, 2026, 1:17 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

NCT07227103
View directory record Official record
Conditions
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
Interventions
Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS, Oral Placebo
Device · Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sarasota, Florida • West Palm Beach, Florida • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

NCT05414422
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
PCN-101, Placebo
Drug
Lead sponsor
Perception Neuroscience
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
13
States / cities
Little Rock, Arkansas • Garden Grove, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Phase 2 Interventional

An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression

NCT00070694
View directory record Official record
Conditions
Depressive Disorder
Interventions
MDL100.907
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 29, 2026, 1:17 PM EDT
Recruiting Not applicable Interventional

One-Day cTBS Over the Precuneus

NCT07758010
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder
Interventions
Precuneus-targeted continuous theta-burst stimulation, Left dorsolateral prefrontal cortex intermittent theta-burst stimulation, Sham transcranial magnetic stimulation
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 29, 2026, 1:17 PM EDT
Completed Phase 2 Interventional

FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression

NCT06620042
View directory record Official record
Conditions
Bipolar Depression, Treatment Resistant Bipolar Depression
Interventions
Ketamine, Functional magnetic resonance imaging (fMRI)
Drug · Other
Lead sponsor
Brian Barnett
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio • Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 29, 2026, 1:17 PM EDT